Back to Research Hub
Arrowhead Pharmaceuticals, Inc.
ARWR
$73.33-0.53 (-0.72%)
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1…
StreetsValue research for Arrowhead Pharmaceuticals, Inc. (ARWR)
Members get the full report for Arrowhead Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.